Navigation Links
Palatin Technologies Announces Receipt of $4.1 Million from AstraZeneca
Date:2/12/2009

Earns Milestone Payment of Additional $2.5 Million

CRANBURY, N.J., Feb. 12 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Alternext US: PTN) today announced it has received $4.1 million from AstraZeneca relating to an extension of its exclusive research collaboration and license agreement to discover, develop and commercialize compounds that target melanocortin receptors and a clinical trial sponsored research agreement.

Palatin also announced that it has earned a milestone payment of $2.5 million in connection with its collaboration and license agreement with AstraZeneca. Palatin anticipates receiving the $2.5 million in the current calendar quarter.

The $6.6 million received or to be received from AstraZeneca, coupled with $1.7 million that Palatin received from the sale of net operating losses to the State of New Jersey, $700,000 from the sale of non-core fixed assets, and its cash and cash equivalents balance, gives Palatin sufficient cash to fund its projected operations through calendar year 2009.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website at www.palatin.com.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit: www.astrazeneca.com

Forward-looking Statements

Statements about future expectations of Palatin Technologies, Inc., including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, marketing collaborations, and all other statements in this document other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Palatin's actual results may differ materially from those discussed in the forward-looking statements for various reasons, including, but not limited to Palatin's ability to fund development of its technology, ability to establish and successfully complete clinical trials and pre-clinical studies and the results of those trials and studies, dependence on its partners for certain development activities, need for regulatory approvals and commercial acceptance of its products, ability to protect its intellectual property, and other factors discussed in the Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008
2. Palatin Technologies to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
3. Stratus Technologies Partners With Infinity Healthcare Solutions to Resell Availability Products With Its Services
4. Dilon Technologies Leads Molecular Breast Imaging Expansion
5. China Medical Technologies to Announce Financial Results for the Third Fiscal Quarter Ended December 31, 2008 on March 2, 2009
6. VNUS Medical Technologies to Present at the Roth 21st Annual OC Growth Stock Conference
7. Greenway Medical Technologies and Navicure Form Partnership to Streamline Claims Management Process
8. ReBuilder Medical Technologies, Inc. to Change Name to American Med Tech
9. Advanced Wound Technologies Mid-Atlantic, Inc. Announces Name Change and Reverse Stock Split
10. ReBuilder Medical Technologies, Inc. (RBRM) Announces Sales Increase In Jan. 09
11. Scribe Healthcare Technologies, LLC to Integrate BenchMark KB™ in Scribe Complete™ Medical Documentation Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... During pregnancy, women are ... erosion, and those dental problems can increase the risk of pregnancy complications. Unfortunately, ... are failing to get the dental care they need. Agoura Hills dentist, Philip ...
(Date:1/17/2017)... ... January 17, 2017 , ... Gym Source, America’s leading retailer ... showroom at South Dixie Hwy in Miami, FL. , “We are elated to be ... new innovative in-store concept is designed to give clients a seamless and motivating shopping ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... improved supplement, Healthful-Flex. , The company, owned and operated by Ed Stroup, ... at a reasonable price with the highest level of customer service. Healthful Balance ...
(Date:1/17/2017)... ... January 17, 2017 , ... Metro Development ... to infusing high speed technology into the fabric of an entire community. A ... of healthcare and wellness in a yet-to-be-named, health focused campus. Leading this initiative ...
(Date:1/17/2017)... ... January 17, 2017 , ... Peoples Health is pleased ... network on Dec. 1, 2016. Peoples Health, a Metairie-based Medicare Advantage company, serves ... exciting addition to our provider network, and the addition will benefit our members ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... 18, 2017 ML Capital ... to publish an online presentation tomorrow, January 19 ... forecast for 2017. Management reports that the forecast ... sales performance from its existing operations, and the ... into the Cannabis sector through a partnership ...
(Date:1/18/2017)... 2017  Astellas Pharma Inc. (President and CEO: ... its participation in Access Accelerated, a global, multi-stakeholder ... prevention, diagnostics and treatment in low-income and lower-middle ... companies and in collaboration with the World Bank ... (UICC), Astellas will work towards the United Nations ...
(Date:1/17/2017)... Jan. 17, 2017 North America Insulin Delivery ... report, "North America Insulin Delivery Market Outlook to 2022", ... Delivery market. The report provides value, in millions of ... within market segments - Insulin Pens, Insulin Pumps, Insulin ... also provides company shares and distribution shares data for ...
Breaking Medicine Technology: